- Home
- CDNA vs CVAC Comparison
CDNA vs CVAC Comparison
Compare CDNA & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- CVAC
- Stock Information
- Founded
- CDNA 1998
- CVAC 2000
- Country
- CDNA United States
- CVAC Germany
- Employees
- CDNA N/A
- CVAC N/A
- Industry
- CDNA Medical Specialities
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- CDNA Health Care
- CVAC Health Care
- Exchange
- CDNA Nasdaq
- CVAC Nasdaq
- Market Cap
- CDNA 1.1B
- CVAC 924.3M
- IPO Year
- CDNA 2014
- CVAC 2020
- Fundamental
- Price
- CDNA $22.94
- CVAC $3.59
- Analyst Decision
- CDNA Buy
- CVAC Hold
- Analyst Count
- CDNA 8
- CVAC 3
- Target Price
- CDNA $26.43
- CVAC $10.00
- AVG Volume (30 Days)
- CDNA 823.5K
- CVAC 1.2M
- Earning Date
- CDNA 02-26-2025
- CVAC 11-12-2024
- Dividend Yield
- CDNA N/A
- CVAC N/A
- EPS Growth
- CDNA N/A
- CVAC N/A
- EPS
- CDNA N/A
- CVAC N/A
- Revenue
- CDNA $312,775,000.00
- CVAC $70,565,734.00
- Revenue This Year
- CDNA $20.27
- CVAC $742.57
- Revenue Next Year
- CDNA $11.76
- CVAC N/A
- P/E Ratio
- CDNA N/A
- CVAC N/A
- Revenue Growth
- CDNA 5.26
- CVAC 75.11
- 52 Week Low
- CDNA $7.42
- CVAC $2.22
- 52 Week High
- CDNA $34.84
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- CDNA 53.43
- CVAC 45.89
- Support Level
- CDNA $21.96
- CVAC $3.70
- Resistance Level
- CDNA $23.80
- CVAC $4.09
- Average True Range (ATR)
- CDNA 1.53
- CVAC 0.22
- MACD
- CDNA 0.09
- CVAC -0.09
- Stochastic Oscillator
- CDNA 45.88
- CVAC 12.05
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.